Tag Archives: pharmaceutical industry

Disordering Normal—Here comes the new DSM

Towards the end of May, the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), the iconic bible of psychiatry, is coming off the presses after much revision and delay. It’s bound to keep people asking, “Am I normal or do I have a mental illness?”

If you think most diseases are established with objective criteria and rigorous debate, you’d be somewhat wrong. The DSM has a strong track record of taking clusters of symptoms and wrapping labels around them, which lead to the accelerated use of some of the most toxic medications on the planet. How does this happen?

TeenScreen—Controversial Mental Health Screening Program Closes Down

A “model” program that was part of a controversial plan to screen all US citizens for mental illness has announced that it is closing down.

On 15 November, TeenScreen, a program to detect depression in young people, announced on its website: “The National Center will be winding down its program at the end of this year.”

ABC News: DSM-5 Criticized for Financial Conflicts of Interest—70% of task force members have ties to Pharma

Controversy continues to swell around the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, better known as DSM-5. A new study suggests the 900-page bible of mental health, scheduled for publication in May 2013, is ripe with financial conflicts of interest.

The manual, published by the American Psychiatric Association, details the diagnostic criteria and recommended treatments — many of which are pharmacological — for each and every psychiatric disorder. After the 1994 release of DSM-4, the APA instituted a policy requiring expert advisors to disclose drug industry ties. But the move toward transparency did little to cut down on conflicts, with nearly 70 percent of DSM-5 task force members reporting financial relationships with pharmaceutical companies — up from 57 percent for DSM-4.

Are Psychiatric Medications Making Us Sicker?

I first took a close look at treatments for mental illness 15 years ago while researching an article for Scientific American. At the time, sales of a new class of antidepressants, selective serotonin reuptake inhibitors, or SSRI’s, were booming. The first SSRI, Prozac, had quickly become the most widely prescribed drug in the world. Many psychiatrists, notably Peter D. Kramer, author of the best seller Listening to Prozac, touted SSRI’s as a revolutionary advance in the treatment of mental illness. Prozac, Kramer said in a phrase that I hope now haunts him, could make patients “better than well.”

Clinical trials told a different story. SSRI’s are no more effective than two older classes of antidepressants, tricyclics and monoamine oxidase inhibitors. What was even more surprising to me—given the rave reviews Prozac had received from Kramer and others—was that antidepressants as a whole were not more effective than so-called talking cures, whether cognitive behavioral therapy or even old-fashioned Freudian psychoanalysis. According to some investigators, treatments for depression and other common ailments work—if they do work—by harnessing the placebo effect, the tendency of a patient’s expectation of improvement to become self-fulfilling. I titled my article “Why Freud Isn’t Dead.” Far from defending psychoanalysis, my point was that psychiatry has made disturbingly little progress since the heyday of Freudian theory.

Big Pharma’s Slimy Crusade to Push Anti-Psychotics on Kids

In the past decade, America’s pharmaceutical industry has knowingly marketed dozens of dangerous drugs to millions of children, a group that executives apparently view as a lucrative, untapped market for their products. Most kids have no one to look out for their interests except anxious parents who put their trust in doctors. As it turns out, that trust is often misplaced. Big Pharma spends massive amounts to entertain physicians, send them on luxury vacations and ply them with an endless supply of free products. As a result, hundreds of thousands of American kids—some as young as three years old—have become dependent on amphetamines like Adderall and a pharmacopeia of other drugs that allegedly treat depression, insomnia, aggression and other mental health disorders.